Oral Administration of Meloxicam and Flunixin Meglumine Have Similar Analgesic Effects After Lipopolysaccharide-Induced Inflammatory Response in Thoroughbred Horses.

The abstract discusses a study on horses that compared the effectiveness and side effects of two drugs, meloxicam and flunixin meglumine, used to treat inflammation and pain resulting from a condition known as systemic inflammatory response syndrome (SIRS)/endotoxemia. The study found that both drugs were effective, with meloxicam showing a similar ability to reduce pain and inflammation, and perhaps being a safer option given its fewer side effects.

Introduction to the Study and Drugs

• The study was aimed at examining the effect of meloxicam (MX), a COX-2 selective inhibitor, in comparison with flunixin meglumine (FM), a nonselective cyclooxygenase (COX) inhibitor.
• Both drugs are used to treat SIRS/endotoxemia in horses. This condition is a severe response to infections or injuries that causes widespread inflammation in the body.
• FM is more frequently chosen for this treatment but it can have significant adverse effects on the gastrointestinal function of horses.

Methodology

• The study involved fifteen horses which were divided into three groups. Each group received a different treatment: MX, FM or saline as placebo.
• The respective drugs were given orally 30 minutes after a Lipopolysaccharide (LPS) challenge, a process used to induce inflammation in the body to mimic the effects of SIRS/endotoxemia.
• The research team kept a record of various clinical parameters such as behavioral pain scores, body temperature, heart rates, respiratory rates, hoof wall surface temperature, leukocyte counts, as well as levels of TNF-α and cortisol. These measures helped them track the inflammatory response and the pain levels of the horses.

Results and Conclusion

• The results of the study suggested that MX and FM both had similar effects in reducing the pain and behavioral symptoms of SIRS/endotoxemia in horses, which were significantly more effective than the placebo group.
• The body temperatures of the horses that received MX or FM were significantly lower compared to the placebo group, indicating a decrease in inflammation. Similar changes were seen in heart rates, respiratory rates, hoof wall surface temperature, and leukocyte counts.
• The levels of TNF-α and cortisol, two indicators of inflammation and stress respectively, were lower in the FM group than in the MX group. However, given the adverse side effects associated with FM, the study suggests that MX could be a more beneficial treatment for horses with SIRS/endotoxemia.